Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.
AffiliationCancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX
MetadataShow full item record
AbstractAll patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. So far, development of a secondary T790M mutation represents the most common (approximately 60%) mechanism of resistance to these drugs. The relative rarity of mesenchymal-epithelial transition (MET) amplification in NSCLC suggests that this event plays a limited role in primary resistance to EGFR-TKI. In contrast, MET gene amplification has been detected as a secondary event representing one of the most relevant mechanisms involved in the acquired resistance to EGFR-TKIs both in preclinical and clinical studies. The aim of this review is to discuss the role of MET amplification as a mechanism of resistance to anti-EGFR therapies and to review strategies which aim at overcoming this mechanism of resistance, including studies assessing drug combinations targeting both EGFR and MET pathways.
CitationRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. 2015, 3 (6):81 Ann Transl Med
JournalAnnals of Translational Medicine
- Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
- Authors: Medical Advisory Secretariat.
- Issue date: 2010
- Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
- Authors: Zhang K, Yuan Q
- Issue date: 2016 Dec
- Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
- Authors: Wang W, Wang H, Lu P, Yu Z, Xu C, Zhuang W, Song Z
- Issue date: 2019 Feb 21
- Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
- Authors: Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K
- Issue date: 2009 Feb 1
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
- Authors: Nguyen KS, Kobayashi S, Costa DB
- Issue date: 2009 Jul